Scribe Therapeutics (NASDAQ:SCTX) Director Acquires $36,107,494.95 in Stock

Scribe Therapeutics Inc. (NASDAQ:SCTX) Director Behzad Aghazadeh purchased 2,383,333 shares of the business’s stock in a transaction on Friday, July 24th. The shares were purchased at an average price of $15.15 per share, with a total value of $36,107,494.95. Following the acquisition, the director directly owned 3,080,983 shares in the company, valued at $46,676,892.45. This represents a 341.62% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Behzad Aghazadeh also recently made the following trade(s):

• On Tuesday, July 28th, Behzad Aghazadeh acquired 7,905 shares of Scribe Therapeutics stock. The stock was purchased at an average cost of $18.25 per share, for a total transaction of $144,266.25.

Scribe Therapeutics Trading Down 4.8%

Shares of NASDAQ SCTX traded down $0.91 during midday trading on Tuesday, reaching $18.06. 428,502 shares of the stock traded hands, compared to its average volume of 423,801. Scribe Therapeutics Inc. has a one year low of $17.31 and a one year high of $25.49.